WO2002043761A1 - Agents anti-obesite et aliments dietetiques - Google Patents
Agents anti-obesite et aliments dietetiques Download PDFInfo
- Publication number
- WO2002043761A1 WO2002043761A1 PCT/JP2001/008847 JP0108847W WO0243761A1 WO 2002043761 A1 WO2002043761 A1 WO 2002043761A1 JP 0108847 W JP0108847 W JP 0108847W WO 0243761 A1 WO0243761 A1 WO 0243761A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibiting
- exchange resin
- function
- substance
- absorption
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention provides a substance that has a function of adsorbing bile acids in the gastrointestinal tract, inhibiting the intestinal circulation, or inhibiting the production of exogenous lipids as an active ingredient.
- An anti-obesity agent and a healthy food characterized by lowering body weight and / or visceral fat mass without accompanying. Background technique
- Hyperlipidosis and diabetes are the greatest risk factors for atherosclerosis, and it is said that treatment of obesity improves them. Fertility treatment is usually based on diet, but there is a need for a drug or a healthy diet that reduces body weight and visceral fat without decreasing the amount of food intake. .
- cholestimide it has been known that choleric acid, oleic acid, monooleic glycerol, and phospholipid (lecithin + Bile acid / lipid complex micelles consisting of lysolecithin) and cholesterol, but only cholate Nevertheless, it has been reported that it shows high adsorptivity to all constituent lipids (Pharmacology and Therapy, 24 (Supp 1.4): 601, 1991) ).
- cholestimid (2-methylethyl) which is known as a cholesterol-lowering agent
- Midazol Epichlorohydro Bile acid adsorption in the gastrointestinal tract as represented by pharmacologically acceptable anion-exchange resins, including but not limited to intestinal circulation.
- the present inventors have found that a substance having an inhibitory effect on body weight can reduce body weight and / or visceral fat without reducing the amount of food intake, leading to completion of the present invention.
- the gist of the invention is that a substance having a function of adsorbing bile acids in the gastrointestinal tract, an effect of inhibiting intestinal circulation, or suppressing the production of exogenous lipids is used as an active ingredient. It is a preferred embodiment of the present invention to reduce body weight and / or visceral fat without lowering the amount of food intake, which is contained in an anti-obesity agent.
- the second aspect of the present invention is that a substance that has a function of adsorbing bile acids in the digestive tract, a function of inhibiting vascular circulation, or a function of inhibiting absorption of exogenous lipids is used as an active ingredient.
- Pharmaceutical compositions for the prevention and / or cure of obesity are mentioned, which are associated with a reduction in body weight and / or visceral fat mass, accompanied by a reduction in food intake.
- a pharmaceutical composition for preventing and / or treating obesity is mentioned as a preferred embodiment.
- the third aspect of the present invention is that a healthy food containing a substance that inhibits the absorption of bile acids in the digestive tract, the inhibitory effect on the vascular circulation, or the inhibitory effect on the absorption of exogenous lipids. It is mentioned that it is preferable to reduce body weight and / or visceral fat without decreasing food intake.
- the gist of the present invention is to use a substance having an action of adsorbing bile acids in the gastrointestinal tract, an action of inhibiting vascular circulation, or an action of inhibiting absorption of exogenous lipids.
- the amount of food that can be eaten For example, there are methods for reducing the amount of high-fat fat.
- Preferred embodiments of the present invention include a substance having a function of adsorbing bile acids in the gastrointestinal tract, a function of inhibiting the intestinal circulation, or a function of inhibiting the absorption of exogenous lipids.
- a pharmacologically acceptable anion-exchange resin is cholestimide, cholesteride Be selected from the group consisting of lancin resin, cholesterol, colesevelam hydrochloride and sevelamellican hydrochloride; and a pharmaceutically acceptable yin ion paternity
- Anion exchange resins formed by the polymerization reaction of epichrom D hydrin derivatives with amides are cited as fats, and are more preferred.
- the pharmaceutically acceptable anion exchange resin is colestimid. Brief description of the lower it is Ru drawings
- FIG. 1 is a graph showing the effect on body weight by the administration of cholestimide used in the examples.
- FIG. 2 is a graph showing the effect on the visceral fat weight due to the administration of cholesteride used in the examples. Best form to carry out the invention
- a substance having an action of adsorbing bile acid in the digestive tract, an action of inhibiting the intestinal circulation, or an action of inhibiting the absorption of exogenous lipids is used.
- the substance is not particularly limited as long as it has a function. Preferably, as shown in the examples below, it has the effect of lowering body weight and / or visceral fat mass without lowering the amount of meals. . Examples of these include pharmaceutically acceptable yin ion exchange. Exchange resins are listed.
- a pharmaceutically acceptable anion-exchange resin is cholestimide (2—methylilemidazole chlorochlorohydrin copolymer). It is listed as the most preferred.
- Cholestimide has a complex structure irregularly disturbed and complex, and is represented by the basic structure of the following formula (I), and the structure is partially represented by the following structure.
- a polymerization reaction of an amide represented by the formula (II) and represented by an epichlorohydrin derivative and an imidazole derivative, ie, disclosed in It can be obtained according to the production method described in Japanese Patent Publication No.
- cholesteryl resin examples include the above-mentioned cholesteryl resin, cholesterol ((chloromethyl) acrylate) N-(2-aminoethyl) to which silane is added-1 'N [1 [(2-aminoethyl) amino] ethyl] 1, 21-ethanediamine polymer), and these are commercially available from Sigma Corporation.
- the cholesterylamine resin is a strongly basic dye containing a styrene-divinylbenzene copolymer which has been added with a quaternary ammonium group. It is an ion exchange resin, and its basic structure is represented by the following formula (III).
- colesevelam hydrochloride is represented by the following formula (IV), and is described in US Pat. No. 5,607,669 or a method analogous thereto. It can be manufactured by
- the above-mentioned compound which is an active ingredient may be used by itself, but the above-mentioned active ingredient can be used by using a general-purpose pharmaceutical additive. It is preferable to manufacture and use a pharmaceutical composition and a health food containing the same.
- Such pharmaceutical compositions and health foods include tablets, capsules, granules, pills, lozenges, liquid preparations, and the like. These are administered orally. When provided as a health food, it can be made into a form such as confectionery.
- Oral pharmaceutical compositions and health foods can be produced in large quantities using conventional compounding methods such as mixing, filling or tableting, or by using repeated compounding operations.
- the active ingredient may be distributed in a pharmaceutical composition or health food using the above filler.
- tablets or capsules used for oral administration The preparations are preferably presented as unit dosages, and include binders, fillers, diluents, tablets, lubricants, disintegrants, colorants, flavors and the like. It may contain commonly used pharmaceutical carriers such as humectants and wetting agents. Tablets are well known in the industry and can be used, for example, as a coating tablet using a coating agent.
- Preferred fillers include cellulose, mannitol, lactose, etc., which are disintegrants. , Polyvinylpyrrolidone, sodium starch, starch derivative such as glycolate, etc., and sodium lauryl sulfate as a lubricant Um, etc. can be used as an additive for pharmaceuticals.
- Pharmaceutical compositions and health foods in liquid form for oral use include, for example, aqueous or oily suspensions, solutions, emeraldion, and syrups. Dry or dry medicine that can be re-dissolved in water or a suitable medium before use, or a pharmaceutical composition such as an excipient or a healthy food, or before use. It is provided as a composition or health food.
- Such liquids may contain the usual additives, for example, sorbitol monosole, syrup, methylcellulose, gelatin, hydroxiechi.
- Precipitating agents such as rucellulose, carboxymethyl recellulose, aluminum stearate gel or hydrogenated edible fat Emulsifiers such as lecithin, sorbitan monooleate and arabia gum; armor oil; rectified coconut oil; Oily esters such as lysine ester; non-producible (such as edible oil) such as propylene glycol and ethyl alcohol Aqueous medium; p-hydroxybenzoic acid methyl ester, ethyl ester or propyl ester, Or preservatives such as sorbic acid and, if necessary, usual flavoring or coloring agents can be combined.
- preservatives such as sorbic acid and, if necessary, usual flavoring or coloring agents can be combined.
- oral pharmaceutical compositions and health foods for example, tablets, capsules, fine granules, etc., usually
- Cholestimide is marketed by Mitsubishi Electric Pharma Co., Ltd. under the trade name Colebin. You can use it as it is.
- the dose of the antiobesity agent of the present invention depends on the patient's age, health condition, weight, severity of the disease, type and frequency of concurrent treatment / treatment, and the nature of the desired effect. It may be determined as appropriate. In general, the daily dose for an adult should be from 1 to 60 g as the active ingredient, and several doses should be administered once a day. . In addition, when provided as a health food, the formulation may be appropriately determined based on the above dosage.
- One group continued to be in a satiety state (saturated group). Also, The three groups were fed once a day at the same level (4.2 g / animal) of 70% of the average daily intake in the fed state.
- the medicines were given water (control group) and cholestimide 62. Smg Z kg or 125 mg Z kg once a day before meals in 3 groups fed the same amount. Oral gavage was administered daily, and no treatment was given to the satiety group.
- Cholestimide was used by suspending an appropriate amount of nose and muscle per weight in 10 mL of water.
- the satiety group, the control group, the colestimide 62.5 mg / kg administration group, and the 125 mg / k administration group Under tel anesthesia, portal venous blood, abdominal major venous blood, and liver and abdominal fat (visceral fat) were collected. The fat in the internal organs was sampled and its wet weight was measured.
- serum lipids include TC (total cholesterol), TG (triglyceride), and PL. (Phospholipids) and FF-II (fat free fatty acids) were measured by conventional methods.
- the weight of the fed group increased gradually, albeit slightly.
- the weight of the control group gradually decreased, and on the 24th day, the average weight decreased by 15.0 g.
- the body weight was also reduced in a dose-related manner (19.2 g in the 62.5 mg / kg group and 1-22 g in the 125 mg / kg group). 8 g) and control throughout the study period Body weight was always lower than in the group. In both groups, the weight was significantly lower than that of the control group.
- the control group showed a decrease of 54.5% (2.91 g) compared to the visceral fat weight (6.39 g) of the satiety group. .
- a dose-dependent decrease was observed in the cholestimide group, 62.9 mg / kg group, 29-9%, and in the 125 mg Z kg group, 46.0%. I was taken.
- the decrease in body weight and visceral fat weight observed in the group receiving cholestimide was not due to a decrease in food intake2, but to bile acids in the gastrointestinal tract. It can be determined to be due to adsorption (inhibition of intestinal circulation) or suppression of exogenous lipid absorption.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01972719A EP1348442A4 (en) | 2000-11-28 | 2001-10-09 | ANTI-OBESITY AGENTS AND DIET FOOD |
CA2430122A CA2430122C (en) | 2000-11-28 | 2001-10-09 | Antiobesity agent and health food |
KR1020037006405A KR100771322B1 (ko) | 2000-11-28 | 2001-10-09 | 항비만제 및 건강식품 |
AU2001292368A AU2001292368A1 (en) | 2000-11-28 | 2001-10-09 | Antiobestic agents and health foods |
CN01819683A CN100594933C (zh) | 2000-11-28 | 2001-10-09 | 抗肥胖剂和健康食品 |
US10/432,877 US7199160B2 (en) | 2000-11-28 | 2001-10-09 | Antiobestic agents and health foods |
JP2002545731A JPWO2002043761A1 (ja) | 2000-11-28 | 2001-10-09 | 抗肥満剤及び健康食品 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000361835 | 2000-11-28 | ||
JP2000-361835 | 2000-11-28 | ||
JP2001037938 | 2001-02-15 | ||
JP2001-37938 | 2001-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002043761A1 true WO2002043761A1 (fr) | 2002-06-06 |
Family
ID=26604749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/008847 WO2002043761A1 (fr) | 2000-11-28 | 2001-10-09 | Agents anti-obesite et aliments dietetiques |
Country Status (8)
Country | Link |
---|---|
US (1) | US7199160B2 (ja) |
EP (1) | EP1348442A4 (ja) |
JP (2) | JPWO2002043761A1 (ja) |
KR (1) | KR100771322B1 (ja) |
CN (1) | CN100594933C (ja) |
AU (1) | AU2001292368A1 (ja) |
CA (1) | CA2430122C (ja) |
WO (1) | WO2002043761A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006070718A1 (ja) * | 2004-12-27 | 2006-07-06 | Banyu Pharmaceutical Co., Ltd. | 全胆汁酸プール量の増減に伴う疾患又は脂質代謝性疾患に対する薬剤及び、それら薬剤のスクリーニング方法 |
JP2009120597A (ja) * | 2007-10-24 | 2009-06-04 | Mitsubishi Tanabe Pharma Corp | 非アルコール性脂肪肝炎の治療および/または予防薬 |
JP2016169388A (ja) * | 2010-02-24 | 2016-09-23 | レリプサ, インコーポレイテッド | 胆汁酸捕捉剤として使用するためのポリイミダゾール |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5930872B2 (ja) | 2012-06-27 | 2016-06-08 | 富士フイルム株式会社 | 染毛剤組成物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4765994A (en) * | 1983-02-23 | 1988-08-23 | Tricum Ab | Method of preparing a water absorbing dietary fibre product |
JPH05186356A (ja) * | 1992-01-10 | 1993-07-27 | Kirin Brewery Co Ltd | 食餌脂質消化吸収阻害材および飲食品 |
WO1997036927A1 (en) * | 1996-03-29 | 1997-10-09 | Dario Boffelli | Amphipathic molecules as cholesterol and other lipid uptake inhibitors |
JPH11147828A (ja) * | 1997-11-17 | 1999-06-02 | Koji Kashima | コレステロール及び脂質吸収阻害剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60209523A (ja) * | 1984-04-03 | 1985-10-22 | Mitsubishi Petrochem Co Ltd | コレステロ−ル低下剤 |
US5137716A (en) * | 1990-11-15 | 1992-08-11 | Weisenfeld Michael S | Method of reducing weight in mammals |
US5380522A (en) * | 1992-08-11 | 1995-01-10 | Day; Charles E. | Method for treatment of irritable bowel syndrome |
US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
CA2129079C (en) * | 1993-08-03 | 2006-01-17 | Tatsuo Nomura | Orally administrable cholesterol lowering agent |
US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
ES2162658T3 (es) * | 1996-03-05 | 2002-01-01 | Mitsubishi Chem Corp | Utilizacion de resinas intercambiadoras anionicas para la fabricacion de un medicamento destinado al tratamiento de la hiperfosfatemia. |
JP4010585B2 (ja) * | 1996-10-15 | 2007-11-21 | 久光製薬株式会社 | 陰イオン交換樹脂を含有する錠剤 |
-
2001
- 2001-10-09 KR KR1020037006405A patent/KR100771322B1/ko not_active IP Right Cessation
- 2001-10-09 CN CN01819683A patent/CN100594933C/zh not_active Expired - Fee Related
- 2001-10-09 AU AU2001292368A patent/AU2001292368A1/en not_active Abandoned
- 2001-10-09 CA CA2430122A patent/CA2430122C/en not_active Expired - Fee Related
- 2001-10-09 JP JP2002545731A patent/JPWO2002043761A1/ja active Pending
- 2001-10-09 EP EP01972719A patent/EP1348442A4/en not_active Ceased
- 2001-10-09 WO PCT/JP2001/008847 patent/WO2002043761A1/ja active Application Filing
- 2001-10-09 US US10/432,877 patent/US7199160B2/en not_active Expired - Fee Related
-
2008
- 2008-04-25 JP JP2008115999A patent/JP2008273969A/ja not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4765994A (en) * | 1983-02-23 | 1988-08-23 | Tricum Ab | Method of preparing a water absorbing dietary fibre product |
JPH05186356A (ja) * | 1992-01-10 | 1993-07-27 | Kirin Brewery Co Ltd | 食餌脂質消化吸収阻害材および飲食品 |
WO1997036927A1 (en) * | 1996-03-29 | 1997-10-09 | Dario Boffelli | Amphipathic molecules as cholesterol and other lipid uptake inhibitors |
JPH11147828A (ja) * | 1997-11-17 | 1999-06-02 | Koji Kashima | コレステロール及び脂質吸収阻害剤 |
Non-Patent Citations (2)
Title |
---|
KATSUHITO TOKUNAGA: "Himan wo gappei shita kou-ketsuatsusou no chiryou", PROG. MED., vol. 20, no. 10, October 2000 (2000-10-01), pages 1979 - 1982, XP002906396 * |
See also references of EP1348442A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006070718A1 (ja) * | 2004-12-27 | 2006-07-06 | Banyu Pharmaceutical Co., Ltd. | 全胆汁酸プール量の増減に伴う疾患又は脂質代謝性疾患に対する薬剤及び、それら薬剤のスクリーニング方法 |
JP2009120597A (ja) * | 2007-10-24 | 2009-06-04 | Mitsubishi Tanabe Pharma Corp | 非アルコール性脂肪肝炎の治療および/または予防薬 |
US8524212B2 (en) | 2007-10-24 | 2013-09-03 | Mitsubishi Tanabe Pharma Corporation | Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis |
JP2016169388A (ja) * | 2010-02-24 | 2016-09-23 | レリプサ, インコーポレイテッド | 胆汁酸捕捉剤として使用するためのポリイミダゾール |
Also Published As
Publication number | Publication date |
---|---|
JPWO2002043761A1 (ja) | 2004-04-02 |
KR20030070027A (ko) | 2003-08-27 |
KR100771322B1 (ko) | 2007-10-29 |
CN100594933C (zh) | 2010-03-24 |
US20040067215A1 (en) | 2004-04-08 |
US7199160B2 (en) | 2007-04-03 |
AU2001292368A1 (en) | 2002-06-11 |
CN1477974A (zh) | 2004-02-25 |
EP1348442A4 (en) | 2005-02-02 |
CA2430122A1 (en) | 2002-06-06 |
CA2430122C (en) | 2010-08-24 |
EP1348442A1 (en) | 2003-10-01 |
JP2008273969A (ja) | 2008-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018304380B2 (en) | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same | |
EP0086079B1 (en) | Composition for reducing weight | |
HUE026628T2 (en) | Pouches for amine polymers | |
JP2002505681A (ja) | 健常人における気分障害を調節するための組成物 | |
AU758181B2 (en) | Therapeutic agents | |
JP2001509173A (ja) | 胃腸リパーゼ阻害剤の使用 | |
US20080249168A1 (en) | Pharmaceutical composition for gout | |
US20100055066A1 (en) | Agent for prophylactic and/or therapeutic treatment of diabetes | |
JP2000504724A (ja) | キトサンとニコチン酸を含む多機能性脂肪吸収剤及び血液コレステロール低下製剤 | |
JPS604802B2 (ja) | 制癌剤 | |
JP2008273969A (ja) | 抗肥満剤及び健康食品 | |
WO2005092349A1 (ja) | インスリン抵抗性改善剤 | |
JPH0529206B2 (ja) | ||
CA1315690C (en) | Synergistic combination of decarboxylase inhibitors and l-dopa pellets | |
JP2000264839A (ja) | 結腸領域で高まった疼痛感応性と関連する機能障害及び/又は下行腸管の疾患の治療及び/又は予防のための医薬調剤並びにその製造法 | |
JP2001048802A (ja) | 糖尿病に有効な健康補助食品およびその使用方法、並びに糖尿病に有効な食品配合剤 | |
KR20020012293A (ko) | 치료제 | |
WO2023212091A1 (en) | Novel ketone ester compounds | |
JPS6260369B2 (ja) | ||
JP4465963B2 (ja) | 高脂血症の予防または改善用組成物 | |
RU2234917C2 (ru) | Терапевтические средства | |
JPH052652B2 (ja) | ||
WO2023156275A1 (en) | Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor | |
JP2004175786A (ja) | I型アレルギー疾患治療用組成物 | |
JPH10152442A (ja) | 抗肥満剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020037006405 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002545731 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2430122 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018196837 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001972719 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037006405 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001972719 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10432877 Country of ref document: US |